AstraZeneca Crestor delay
Executive Summary
AstraZeneca expects an "approvable" letter for cholesterol agent Crestor (rosuvastatin) at the end of June, consistent with a 12-month user fee deadline, rather than original 10-month expectation. FDA is seeking data and analyses "to support the use of Crestor at higher doses," company says. The 80 mg dose was associated with rhabdomyolysis in Phase III trials (1"The Pink Sheet" Feb. 4, p. 25). The launch will be delayed beyond the third quarter...
You may also be interested in...
AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests
AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.